• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Infect Dis . Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort

tetano

Editor, Senior Moderator
BMC Infect Dis


. 2022 Jan 9;22(1):41.
doi: 10.1186/s12879-021-06973-0.
Prevalence of SARS-Cov-2 antibodies and living conditions: the French national random population-based EPICOV cohort


Josiane Warszawski[SUP] 1 [/SUP], Anne-Lise Beaumont[SUP] 2 [/SUP], Rémonie Seng[SUP] 3 [/SUP], Xavier de Lamballerie[SUP] 4 [/SUP], Delphine Rahib[SUP] 5 [/SUP], Nathalie Lydié[SUP] 5 [/SUP], Rémy Slama[SUP] 6 [/SUP], Sylvain Durrleman[SUP] 7 [/SUP], Philippe Raynaud[SUP] 8 [/SUP], Patrick Sillard[SUP] 9 [/SUP], François Beck[SUP] 5 [/SUP], Laurence Meyer[SUP] 2 [/SUP], Nathalie Bajos[SUP] 10 [/SUP], EPICOV study group



Collaborators, Affiliations

Abstract

Background: We aimed to estimate the seroprevalence of SARS-CoV-2 infection in France and to identify the populations most exposed during the first epidemic wave.
Methods: Random selection of individuals aged 15 years or over, from the national tax register (96% coverage). Socio-economic data, migration history, and living conditions were collected via self-computer-assisted-web or computer-assisted-telephone interviews. Home self-sampling was performed for a random subsample, to detect IgG antibodies against spike protein (Euroimmun), and neutralizing antibodies with in-house assays, in dried blood spots (DBS).
Results: The questionnaire was completed by 134,391 participants from May 2nd to June 2st, 2020, including 17,441 eligible for DBS 12,114 of whom were tested. ELISA-S seroprevalence was 4.5% [95% CI 3.9-5.0] overall, reaching up to 10% in the two most affected areas. High-density residences, larger household size, having reported a suspected COVID-19 case in the household, working in healthcare, being of intermediate age and non-daily tobacco smoking were independently associated with seropositivity, whereas living with children or adolescents did not remain associated after adjustment for household size. Adjustment for both residential density and household size accounted for much of the higher seroprevalence in immigrants born outside Europe, twice that in French natives in univariate analysis.
Conclusion: The EPICOV cohort is one of the largest national representative population-based seroprevalence surveys for COVID-19. It shows the major role of contextual living conditions in the initial spread of COVID-19 in France, during which the availability of masks and virological tests was limited.

Keywords: COVID-19; Population-based survey; Random sample; Risk factors; SARS-COV-2; Seroprevalence.
 
Back
Top Bottom